File Download
  Patent History
  • Application
    CN 20098128192 2009-07-14
  • Publication
    CN 102239179 2011-11-09
Supplementary

published patent: Integrin peptide, anti-cd 18 ssa antibody for treatment of endotoxin-mediated pro-inflammatory responses and the use

TitleIntegrin peptide, anti-cd 18 ssa antibody for treatment of endotoxin-mediated pro-inflammatory responses and the use
Priority Date2009-07-14 PCT/CN2009000791
2008-07-14 US 12/080558P
Inventors
Issue Date2011
Citation
China Published Patent Application CN 102239179. Beijing, PRC: State Intellectual Property Office (SIPO) of the P.R.C., 2011 How to Cite?
AbstractBacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD 18 ssA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis.
Persistent Identifierhttp://hdl.handle.net/10722/176642

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:38:17Z-
dc.date.available2012-11-30T08:38:17Z-
dc.date.issued2011-
dc.identifier.citationChina Published Patent Application CN 102239179. Beijing, PRC: State Intellectual Property Office (SIPO) of the P.R.C., 2011en_HK
dc.identifier.urihttp://hdl.handle.net/10722/176642-
dc.description.abstractBacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD 18 ssA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documentsen_US
dc.titleIntegrin peptide, anti-cd 18 ssa antibody for treatment of endotoxin-mediated pro-inflammatory responses and the useen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorLuk, JMCen_HK
dc.contributor.inventorWong Kwongfaien_HK
dc.contributor.inventorPoon, RTPen_HK
dc.contributor.inventorFan, STen_HK
patents.identifier.applicationCN 20098128192en_HK
patents.identifier.applicationZL200980128192.1-
patents.description.assigneeUNIV HONG KONGen_HK
patents.description.countryChina, PRCen_HK
patents.date.publication2011-11-09en_HK
patents.identifier.hkutechidSurg-2007-00270-2-
patents.date.application2009-07-14en_HK
patents.date.priority2009-07-14 PCT/CN2009000791en_HK
patents.date.priority2008-07-14 US 12/080558Pen_HK
patents.description.ccCNen_HK
patents.identifier.publicationCN 102239179en_HK
patents.relation.familyCN 102239179 (A) 2011-11-09en_HK
patents.relation.familyUS 2010008925 (A1) 2010-01-14en_HK
patents.relation.familyUS 7960338 (B2) 2011-06-14en_HK
patents.relation.familyWO 2010006508 (A1) 2010-01-21en_HK
patents.description.kindAen_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats